

Additional file 2. Change from baseline in **(A)** fasting lipids, **(B)** plasma/serum renal biomarkers, and **(C)** bone biomarkers at Week 48 by age: TANGO and SALSA pooled safety population. Treatment ratio (lipids) or treatment difference (renal and bone biomarkers) (95% CI) shown above or below bars. BMI, body mass index; CAR, current antiretroviral regimen; DTG, dolutegravir; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 3TC, lamivudine. Adjustment terms included treatment, visit, age, sex, race, baseline value (log-transformed for lipids), baseline third agent class, baseline CD4+ cell count, treatment-by-visit interaction, baseline value (log-transformed for lipids)-by-visit interaction, and study, with visit as the repeated factor; subgroup analyses by age were also adjusted for visit-by-age, treatment-by-age, and treatment-by-visit-by-age interactions. ^aFor renal biomarkers, baseline BMI, diabetes, and hypertension were additional adjustment terms. ^bFor bone biomarkers, baseline BMI, smoking history, and vitamin D use were additional adjustment terms.

